Company / Cash & Equivalents
Ultragenyx Pharmaceutical Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$421.0M
FY2025
5-year range
$132.9M / $713.5M
FY2021-FY2025
Trend
+142.0%
vs FY2024
Sector context
#48 of 207
Health Care
What the data says
Ultragenyx Pharmaceutical Inc.'s cash & equivalents of $421M is higher than 77% of companies in the Health Care sector (FY2025). Cash & Equivalents has fluctuated over the past 10 years, ranging from $24M in FY2016 to $714M in FY2021.
Based on SEC 10-K filings.
$421M in FY2025 with a 5-year CAGR of -0.6%. Top quartile in the Health Care sector.
Improved from $214M to $421M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +46.8%
- 5-Year CAGR
- -0.6%
- 10-Year CAGR
- -
Sector benchmark
-37.1% below sector average
Key checks
Key Insights
- 5-year CAGR of -0.6%, indicating a declining trend.
- In FY2025, cash & equivalents increased 142.0% year-over-year.
- Ranks #48 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -2.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $421.0M | +142.0% |
| FY2024 | $174.0M | -18.7% |
| FY2023 | $214.0M | +61.0% |
| FY2022 | $132.9M | -81.4% |
| FY2021 | $713.5M | +64.6% |
| FY2020 | $433.6M | +282.2% |
| FY2019 | $113.4M | +0.0% |
| FY2018 | $113.4M | -29.6% |
| FY2017 | $161.1M | +562.4% |
| FY2016 | $24.3M | -74.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026